Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion for ...
Napp’s Pelmeg, a biosimilar of Amgen’s cancer drug Neulasta (pegfilgrastim), has been launched in the UK following approval late last year. This is Napp’s first launch of a product developed by Cinfa ...
Our data is for sale — everything from our Social Security numbers to our browsing histories. Data brokers sell our personal details to other companies for marketing, credit reporting, debt collection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback